Julia Oto1, Emma Plana1,2, José Vicente Sánchez-González3, Jorge García-Olaverri4, Álvaro Fernández-Pardo1, Francisco España1, Manuel Martínez-Sarmiento3, César D Vera-Donoso3, Silvia Navarro1, Pilar Medina5,6. 1. Haemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, Medical Research Institute of Hospital La Fe, Fernando Abril Martorell 106, 46026, Valencia, Spain. 2. Angiology and Vascular Surgery Service, La Fe University and Polytechnic Hospital, Fernando Abril Martorell 106, 46026, Valencia, Spain. 3. Department of Urology, La Fe Hospital, Fernando Abril Martorell 106, 46026, Valencia, Spain. 4. Department of Urology, Hospital de Cruces, Baracaldo, Plaza de Cruces, S/N, 48903, Baracaldo, Vizcaya, Spain. 5. Haemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, Medical Research Institute of Hospital La Fe, Fernando Abril Martorell 106, 46026, Valencia, Spain. medina_pil@gva.es. 6. IIS La Fe-Hospital Universitario y Politécnico La Fe, Torre A, 5ª Planta, Lab. 5-09, Av. Fernando Abril Martorell 106, 46026, Valencia, Spain. medina_pil@gva.es.
Abstract
PURPOSE OF REVIEW: Renal cell carcinoma (RCC) is the third most common urologic malignancy. First symptoms are usually unspecific and belated causing the stages to be high when diagnosed. As compensation, incidental detection of RCC by abdominal imaging techniques for other medical purposes is a reality that favours a decrease in the stage of new diagnosed tumours. Therefore, identifying novel predictive biomarkers for diagnosis, progression and prognosis of RCC is fundamental. RECENT FINDINGS: To date, several studies have demonstrated that microRNAs (miRNAs) play a role in the particular scenario of urologic tumors, and alterations at miRNA level are involved in the initiation, progression and metastases formation of renal cancer. In the present review, we have summarized the up‑to‑date preliminary clinical works on the role of urinary miRNA profiling in RCC, including an evaluation of its value as a potential biomarker for diagnosis, prognosis and follow up of RCC patients.
PURPOSE OF REVIEW: Renal cell carcinoma (RCC) is the third most common urologic malignancy. First symptoms are usually unspecific and belated causing the stages to be high when diagnosed. As compensation, incidental detection of RCC by abdominal imaging techniques for other medical purposes is a reality that favours a decrease in the stage of new diagnosed tumours. Therefore, identifying novel predictive biomarkers for diagnosis, progression and prognosis of RCC is fundamental. RECENT FINDINGS: To date, several studies have demonstrated that microRNAs (miRNAs) play a role in the particular scenario of urologic tumors, and alterations at miRNA level are involved in the initiation, progression and metastases formation of renal cancer. In the present review, we have summarized the up‑to‑date preliminary clinical works on the role of urinary miRNA profiling in RCC, including an evaluation of its value as a potential biomarker for diagnosis, prognosis and follow up of RCCpatients.
Authors: Elena Arance; Viviana Ramírez; Alejandro Rubio-Roldan; Francisco M Ocaña-Peinado; Catalina Romero-Cachinero; Ana Belén Jódar-Reyes; Fernando Vazquez-Alonso; Luis Javier Martinez-Gonzalez; Maria Jesus Alvarez-Cubero Journal: Cancers (Basel) Date: 2021-12-31 Impact factor: 6.639
Authors: Julia Oto; Emma Plana; María José Solmoirago; Álvaro Fernández-Pardo; David Hervás; Fernando Cana; Francisco España; Andrea Artoni; Paolo Bucciarelli; Giorgio Carrabba; Silvia Navarro; Giuliana Merati; Pilar Medina Journal: Cancers (Basel) Date: 2020-06-11 Impact factor: 6.639